Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PRIVIA HEALTH GROUP, INC.

(PRVA)
  Report
Delayed Nasdaq  -  04:00:00 2023-06-08 pm EDT
27.80 USD   +9.97%
10:52aEXp World to Replace Heska, Privia Health to Replace Ruth's Hospitality on S&P SmallCap 600; Shares Rise
MT
04:50aEXp World to Replace Heska, Privia Health to Replace Ruth's Hospitality on S&P SmallCap 600
MT
06/04Certain Common Stock of Privia Health Group, Inc. are subject to a Lock-Up Agreement Ending on 4-JUN-2023.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Privia Health Group, Inc. : Underpinned by a support level

05/23/2023 | 02:28am EDT
long trade
Stop-loss triggered
Entry price : 26.21$ | Target : 29.93$ | Stop-loss : 24$ | Potential : 14.19%
The support at 24.72 USD, which is currently being tested, should allow Privia Health Group, Inc. shares to move back to the upside.
Investors have an opportunity to buy the stock and target the $ 29.93.
Privia Health Group, Inc. : Privia Health Group, Inc. : Underpinned by a support level
Summary
  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 68% by 2025.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses
  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company sustains low margins.
  • With an expected P/E ratio at 100.73 and 70.07 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

ę MarketScreener.com 2023

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2023 1 608 M - -
Net income 2023 30,2 M - -
Net cash 2023 389 M - -
P/E ratio 2023 100x
Yield 2023 -
Capitalization 2 924 M 2 924 M -
EV / Sales 2023 1,58x
EV / Sales 2024 1,27x
Nbr of Employees 964
Free-Float 89,5%
Upcoming event on PRIVIA HEALTH GROUP, INC.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 25,28 $
Average target price 38,69 $
Spread / Average Target 53,0%
EPS Revisions
Managers and Directors
Matthew Shawn Morris Chief Executive Officer & Director
Parth Mehrotra President & Chief Operating Officer
David Mountcastle Chief Financial Officer & Executive Vice President
David P. King Non-Executive Chairman
Keith Fernandez Chief Clinical Officer
Secure and increase the performance of your investments with our team of experts at your side.
Securing my Investments
fermer